Literature DB >> 7584112

Inhibition of HIV-1 in CEM cells by a potent TAR decoy.

S W Lee1, H F Gallardo, O Gaspar, C Smith, E Gilboa.   

Abstract

TAR decoys are short RNA oligonucleotides, corresponding to the HIV TAR sequence, which inhibit HIV expression and replication by blocking the binding of the HIV regulatory protein Tat to the authentic TAR region. In previous studies, TAR decoys expressed from a tRNA polIII promoter were moderately effective at inhibiting HIV in isolated human T cell lines and less effective at inhibiting HIV in peripheral blood CD4+ T cells. In this study, a series of modifications was introduced into the tRNA expression cassette in order to improve their effectiveness. These modifications included the addition of sequences which are predicted to have stem-loop secondary structures and addition of a wild-type tRNA processing site. TAR decoy RNA expressed in CEM cells from modified tRNA-based expression cassettes yielded five- to 20-fold more TAR transcripts than unmodified tRNA-based expression cassettes. HIV replication, as measured by a flow cytometric method to quantify intracellular viral p24 expression, was significantly reduced in polyclonal populations of CEM cells expressing a modified tRNA-TAR transcript that contains a wild-type tRNA processing site and stem-loops 5' and 3' to the TAR sequence. Similar modifications to the tRNA expression cassette also increased the intracellular concentration of a random test oligonucleotide, indicating that this improved expression system may also be useful for antisense and ribozyme based gene inhibition strategies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584112

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  11 in total

Review 1.  Gene therapy for HIV.

Authors:  A M Lever
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  A nucleolar TAR decoy inhibitor of HIV-1 replication.

Authors:  Alessandro Michienzi; Shirley Li; John A Zaia; John J Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-10       Impact factor: 11.205

3.  Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers.

Authors:  X Wei; M Götte; M A Wainberg
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

4.  Nucleic acid aptamers for target validation and therapeutic applications.

Authors:  P Shannon Pendergrast; H Nicholas Marsh; Dilara Grate; Judith M Healy; Martin Stanton
Journal:  J Biomol Tech       Date:  2005-09

5.  The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat.

Authors:  K Fujinaga; T P Cujec; J Peng; J Garriga; D H Price; X Graña; B M Peterlin
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  A high affinity binding site for the HIV-1 nucleocapsid protein.

Authors:  J A Berglund; B Charpentier; M Rosbash
Journal:  Nucleic Acids Res       Date:  1997-03-01       Impact factor: 16.971

7.  Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy.

Authors:  C M Browning; L Cagnon; P D Good; J Rossi; D R Engelke; D M Markovitz
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

8.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

9.  Inhibition of HIV/SIV replication by dominant negative Gag mutants.

Authors:  R Shimano; R Inubushi; Y Oshima; A Adachi
Journal:  Virus Genes       Date:  1999       Impact factor: 2.198

10.  Co-expression of anti-NFkappaB RNA aptamers and siRNAs leads to maximal suppression of NFkappaB activity in mammalian cells.

Authors:  Robert Chan; Madaline Gilbert; Kristin M Thompson; H Nicholas Marsh; David M Epstein; P Shannon Pendergrast
Journal:  Nucleic Acids Res       Date:  2006-03-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.